In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised the price …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (NASDAQ:BLRX) with a price target of …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a price target …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN), and raised his price …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on MEI Pharma (NASDAQ:MEIP) with a price target …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Can-Fite BioPharma (NYSE:CANF) with a price target …
In a research note published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies (NYSE: PTN) with a $6 …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $30 price target. The report comes ahead of the FDA’s long-anticipated …
Ligand Pharma (NASDAQ:LGND) partner GlaxoSmithKline (NYSE:GSK) announced it received FDA approval for the sNDA of Promacta for treatment of cytopenia in patients with …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a price target of …
